ELTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Elicio Therapeutics Inc (ELTX) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show some bullish trends, the lack of significant positive catalysts, poor financial performance, and no recent trading signals from Intellectia Proprietary Trading Signals suggest that this stock does not present an optimal entry point right now.
The MACD is positive but contracting, RSI is neutral at 50.908, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the price is below the pivot level of 11.925, indicating potential resistance. Support levels are at 10.439 and 9.521, while resistance levels are at 13.411 and 14.329.
Analysts have a positive outlook with multiple 'Buy' ratings and price targets ranging from $17 to $20, citing the potential of ELI-002 as a paradigm shift in mKRAS immunotherapy. The stock also shows a 60% chance of gaining 14.16% in the next month based on candlestick pattern analysis.
There is no recent news or significant trading activity from hedge funds, insiders, or Congress. Additionally, no Intellectia Proprietary Trading Signals were triggered, and the stock's post-market change is negative (-1.10%).
In Q4 2025, the company reported no revenue growth (0% YoY), a net income drop of -44.89% YoY to -$7.72M, and a decline in EPS by -51.46% YoY to -0.5. Gross margin remained at 0%.
Analysts are optimistic about ELTX, with recent 'Buy' ratings and price targets of $17-$20. Ladenburg sees the company as setting a new standard in pancreatic cancer care, while H.C. Wainwright increased the probability of success for ELI-002 to 50%.
